Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology.

By Børge G. Nordestgaard. Circulation Research, 2016

934 citations recorded by the source corpus.

Subfields: Cancer Research, Endocrinology, Diabetes and Metabolism, Surgery

View Paper: https://www.semanticscholar.org/paper/ab99253b687640c654297267290c966256d9dcd0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Endocrinology, Diabetes and Metabolism

In Surgery

Citations in the corpus

Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society (2021, methodology): “17,86 These include the remnant-like particle assay 68,158,159 and a direct assay of TRL cholesterol.”
2020 International Society of Hypertension global hypertension practice guidelines. (2020, background): “Statins are the lipid-lowering treatment of choice with or without ezetimibe and/or PCSK9 inhibitor (in the optimal setting) [98].”
Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel (2020, background): “and Lp(a) are directly causal in ASCVD, independent of LDL-C levels.(6,7,9,11) Indeed, the hazard ratios for myocardial infarction for a”
Immunity and Inflammation in atherosclerosis (2019, background): “ApoB-containing triglyceride-rich remnant particles also show a strong association with cardiovascular disease, inflammation, and immune pathways.(7) Indeed, LDL as (auto) antigen was first suggested by Gero et al(38) in 1959: immunization with LDL protected against atherosclerosis in rabbits, sugge”